본문 바로가기
KERD
논문KCI 등재

두경부암의 표적치료: Epidermal Growth Factor Receptor의 한계 및 이를 극복하는 새로운 표적

Molecular Targeted Therapy of Head and Neck Cancer: Promising Molecular Targets of Post-Epidermal Growth Factor Receptor Era

김철호|장재원
대한이비인후과학회 (Korean Society of Otorhinolaryngology-Head and Neck Surgery)|2014.09|대한이비인후과학회지 두경부외과학 (Korean Journal of Otorhinolaryngology-Head and Neck Surgery)|제57권 제9호|pp. 575-583|DOI http://dx.doi.org/10.3342/kjorl-hns.2014.57.9.575

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Molecular targeted therapyHead and neck squamous cell carcinomaEGFR inhibitor resistanceOvercoming resistance
주제분류이비인후과학

초록

Head and neck squamous cell carcinoma (HNSCC) affects over half a million people worldwide. Despite advances in biology and medicine, only half of the patients are alive in 5 years. The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of HNSCC cases, and it is correlated with poor responses to therapy and worse prognosis. Multiple therapies targeting this pathway have been tested. However, only a minority of patients has showed meaningful responses to these agents and almost all who do develop acquired tumor resistance after a few months of treatment. Recently, a significant interest has focused on identifying mechanisms of acquired and de novo resistance of EGFR blockage. In addition, other inhibitors of EGFR that interfere with known molecular pathways activated in HNSCC have been studied extensively, either as single agents or in combination with other treatment modalities. Here we review some of EGFR resistance mechanisms and briefly discuss new molecular therapeutic strategies to overcome that resistance in HNSCC. Korean J Otorhinolaryngol-Head Neck Surg 2014;57(9):575-83

Abstract

Head and neck squamous cell carcinoma (HNSCC) affects over half a million people worldwide. Despite advances in biology and medicine, only half of the patients are alive in 5 years. The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of HNSCC cases, and it is correlated with poor responses to therapy and worse prognosis. Multiple therapies targeting this pathway have been tested. However, only a minority of patients has showed meaningful responses to these agents and almost all who do develop acquired tumor resistance after a few months of treatment. Recently, a significant interest has focused on identifying mechanisms of acquired and de novo resistance of EGFR blockage. In addition, other inhibitors of EGFR that interfere with known molecular pathways activated in HNSCC have been studied extensively, either as single agents or in combination with other treatment modalities. Here we review some of EGFR resistance mechanisms and briefly discuss new molecular therapeutic strategies to overcome that resistance in HNSCC. Korean J Otorhinolaryngol-Head Neck Surg 2014;57(9):575-83

참고문헌 (57)

  1. Simard EP, "International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site", Oral Oncol, 50(5), pp.387~403 (2014)
  2. Ang KK, "Human papillomavirus and survival of patients with oropharyngeal cancer", N Engl J Med, 363(1), pp.24~35 (2010)
  3. Grégoire V, "Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 21(Suppl 5), pp.v184~v186 (2010)
  4. Jaiswal G, "Field cancerization: concept and clinical implications in head and neck squamous cell carcinoma", J Exp Ther Oncol, 10(3), pp.209~214 (2013)
  5. Ward BB, "Targeted therapy in head and neck cancer", Oral Maxillofac Surg Clin North Am, 25(1), pp.83~92 (2013)
  6. Schmitz S, "Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions", Cancer Treat Rev, 40(3), pp.390~404 (2014)
  7. Keysar SB, "Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer", Cancer Res, 73(11), pp.3881~3892 (2013)
  8. Zhang L, "ERBB3", HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models, 2014, pp.13(5), 1345~1355
  9. Yarden Y, "Untangling the ErbB signalling network", Nat Rev Mol Cell Biol, 2(2), pp.127~137 (2001)
  10. Cooper JB, "Mechanisms of resistance to EGFR inhibitors in head and neck cancer", Head Neck, 31(8), pp.1086~1094 (2009)
  11. Rabinowits G, "Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature", Oral Oncol, 48(11), pp.1085~1089 (2012)
  12. Gandhi MD, "Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib", Onco Targets Ther, 7, pp.245~251 (2014)
  13. Zalcman G, "EGFR pathway and mechanism of action of tyrosine kinase inhibitors", Rev Pneumol Clin, 63(1 PT 2), pp.2S5~2S6 (2007)
  14. Lenz HJ, "Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events", Oncology (Williston Park), 20(5 Suppl 2), pp.5~13 (2006)
  15. Correale P, "Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR)expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC)", Eur J Cancer, 46(9), pp.1703~1711 (2010)
  16. Ratushny V, "Targeting EGFR resistance networks in head and neck cancer", Cell Signal, 21(8), pp.1255~1268 (2009)
  17. Wheeler DL, "Understanding resistance to EGFR inhibitors-impact on future treatment strategies", Nat Rev Clin Oncol, 7(9), pp.493~507 (2010)
  18. Ciardiello F, "Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor", Clin Cancer Res, 7(5), pp.1459~1465 (2001)
  19. Bianco R, "Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells", Clin Cancer Res, 14(16), pp.5069~5080 (2008)
  20. Sok JC, "Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting", Clin Cancer Res, 12(17), pp.5064~5073 (2006)
  21. Wheeler DL, "Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab", Cancer Biol Ther, 8(8), pp.696~703 (2009)
  22. Lu Y, "Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab", Cancer Res, 67(17), pp.8240~8247 (2007)
  23. Wang SC, "Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors", Clin Cancer Res, 15(21), pp.6484~6489 (2009)
  24. Xia W, "Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer", Mol Carcinog, 4(7), pp.610~617 (2009)
  25. Li C, "Nuclear EGFR contributes to acquired resistance to cetuximab", Oncogene, 28(43), pp.3801~3813 (2009)
  26. Fuchs BC, "Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells", Cancer Res, 68(7), pp.2391~2399 (2008)
  27. Engelman JA, "ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines", Proc Natl Acad Sci U S A, 102(10), pp.3788~3793 (2005)
  28. Guix M, "Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins", J Clin Invest, 118(7), pp.2609~2619 (2008)
  29. Harrington K, "Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease", Eur J Cancer, 49(7), pp.1609~1618 (2013)
  30. Schaefer G, "A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies", Cancer Cell, 20(4), pp.472~486 (2011)
  31. Trusolino L, "MET signalling: principles and functions in development, organ regeneration and cancer", Nat Rev Mol Cell Biol, 11(2), pp.834~848 (2010)
  32. Xu H, "Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells", Clin Cancer Res, 17(13), pp.4425~4438 (2011)
  33. Knowles LM, "HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer", Clin Cancer Res, 15(11), pp.3740~3750 (2009)
  34. Schmitz S, "Phase II study of figitumumab in patients with recurrent and", or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)., 2012, pp.23(8), 2153~2161
  35. Seiwert TY, "Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer", J Clin Oncol, 26(10), pp.1732~1741 (2008)
  36. Fury MG, "A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III", IVB head and neck squamous cell cancer, 2012, pp.118(20), 5008~5014
  37. Argiris A, "Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck", Ann Oncol, 24(1), pp.220~225 (2013)
  38. Machiels JP, "Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01", J Clin Oncol, 28(1), pp.21~28 (2010)
  39. Williamson SK, "Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420", J Clin Oncol, 28(20), pp.3330~3335 (2010)
  40. Sano D, "Vandetanib restores head and neck squamous cell carcinoma cells’ sensitivity to cisplatin and radiation in vivo and in vitro", Clin Cancer Res, 17(7), pp.1815~1827 (2011)
  41. Cassell A, "Targeting TORC1", 2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models, 2012, pp.14(11), 1005~1014
  42. Bauman JE, "A phase II study of temsirolimus and erlotinib in patients with recurrent and", or metastatic, platinum-refractory head and neck squamous cell carcinoma, 2013, pp.49(5), 461~467
  43. Sen M, "Targeting Stat3 abrogates EGFR inhibitor resistance in cancer", Clin Cancer Res, 18(18), pp.4986~4996 (2012)
  44. Raju U, "Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways", Radiother Oncol, 105(2), pp.241~249 (2012)
  45. Brooks HD, "Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma", Cancer, 117(10), pp.2112~2119 (2011)
  46. Lin YC, "Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells", Neoplasia, 14(6), pp.463~475 (2012)
  47. Chung CH, "Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and", or metastatic head and neck squamous cell carcinoma, 2010, pp.21(4), 864~870
  48. Argiris A, "Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer", Clin Cancer Res, 17(17), pp.5755~5764 (2011)
  49. Gilbert J, "Phase II 2-arm trial of the proteasome inhibitor, PS-341(bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group", Head Neck, 35(7), pp.942~948 (2013)
  50. Rikiishi H, "Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid", Int J Oncol, 30(5), pp.1181~1188 (2007)
  51. Okui T, "Antitumor effect of novel HSP90 inhibitor NVP-AUY922against oral squamous cell carcinoma", Anticancer Res, 31(4), pp.1197~1204 (2011)
  52. Lin JT, "Association of high levels of Jagged-1 and Notch-1 expression with poor prognosis in head and neck cancer", Ann Surg Oncol, 17(11), pp.2976~2983 (2010)
  53. Gu F, "Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma", Oncol Rep, 23(3), pp.671~676 (2010)
  54. Machiels JP, "Biologically based treatment in head and neck squamous cell carcinoma (HNSCC)", Ann Oncol, 23(suppl 9), pp.ix42~ix43 (2012)
  55. Burtness B, "Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition", Lancet Oncol, 14(8), pp.e302~e309 (2013)
  56. Martini M, "Targeted therapies: how personal should we go?", Nat Rev Clin Oncol, 9(2), pp.87~97 (2011)
  57. Gerlinger M, "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing", N Engl J Med, 366(10), pp.883~892 (2012)

관련 논문AI추천

두경부암의 EGFR 표적 치료최승호대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2007 · 제50권 제3호두경부암의 방사선 저항성 기전 및 극복방안 연구한명월대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2023 · 제66권 제5호두경부 편평상피세포암에 대한 최근 약제 개발과 연구 방향이윤세대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2019 · 제62권 제9호Mutations in the tyrosine kinase domain of the EGFR gene are rare in the Korean Oral Squamous Cell Carcinoma이은주한국컴퓨터정보학회 · 한국컴퓨터정보학회논문지2016 · 제21권 제9호국소 재발한 두경부암의 치료권민수대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2022 · 제65권 제3호Growth inhibition in head and neck cancer cell lines by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor김명진, 송승일대한구강악안면외과학회 · 대한구강악안면외과학회지2009 · 제35권 제5호

이 간행물의 다른 논문 (10건)

소음성 난청의 현재신시옥pp. 584-588Ouabain에 의해 유도된 선택적 나선신경절 세포손상이태훈, 배우용, 김재룡, 김보영pp. 589-595이명의 유병기간과 동반 청력손실이 인지행동치료에 미치는 효과지연숙, 김은옥, 이효정, 김형종, 홍성광pp. 596-602옴나리스Ⓡ에 의한 비용상피세포 염증반응 및 점액유전자 발현 억제진효승, 김이혁, 강승현, 신승헌, 예미경pp. 603-609성대결절에서 보툴리늄독소주입술의 효과안철민pp. 610-615
원문 보기